Filed pursuant to Rule 433
Issuer Free Writing Prospectus dated September 21, 2006
Relating to Preliminary Prospectus dated September 8, 2006
Registration Statement No. 333-134311
Issuer Free Writing Prospectus dated September 21, 2006
Relating to Preliminary Prospectus dated September 8, 2006
Registration Statement No. 333-134311
ImaRx Therapeutics, Inc.
On September 21, 2006, ImaRx Therapeutics, Inc. filed Amendment No. 4 to its Registration
Statement on Form S-1 to update certain disclosures that had been provided in its Preliminary
Prospectus dated September 8, 2006. The disclosures in the preliminary prospectus included in
Amendment No. 4 to the Registration Statement that did not appear in the disclosure in the
Preliminary Prospectus dated September 8, 2006 are set forth below. References to “ImaRx,” “we,”
“us” and “our” are used in the manner described in the Preliminary Prospectus dated September 8,
2006.
Under the caption “Business—Material Contracts—Clinical Research Agreement with INC
RESEARCH, Inc. on page 64 of the preliminary prospectus included in Amendment No. 4 to the
Registration Statement, we added the following disclosure:
Clinical Research Agreement with INC RESEARCH, Inc.
On September 11, 2006, we entered into a clinical research and related services agreement with
INC RESEARCH, Inc., or INC, pursuant to which INC will assist us in making preparations to conduct a Phase
1/2 dose-escalation clinical trial that will employ our proprietary SonoLysis bubbles, ultrasound
and tPA. Upon signing the agreement, we made a payment to INC of $200,000, which amount will be
applied against amounts that accrue and become due to INC for future services under the agreement.
We estimate that costs and fees for all services to be provided under the agreement total
approximately $1.6 million. We will be obligated to pay fees and to reimburse INC for direct and
indirect costs incurred by them under the agreement within 30 days after our receipt of invoices
provided from time to time by INC. The agreement will terminate on December 1, 2006 unless earlier
terminated by either party upon 30 days written notice to the other party.
To review a filed copy of our current registration statement, click on the following link:
THE ISSUER HAS FILED A REGISTRATION STATEMENT (INCLUDING A PROSPECTUS) WITH THE SECURITIES AND
EXCHANGE COMMISSION, OR THE SEC, FOR THE OFFERING TO WHICH THIS COMMUNICATION RELATES. BEFORE YOU
INVEST, YOU SHOULD READ THE PROSPECTUS IN THAT REGISTRATION STATEMENT AND OTHER DOCUMENTS THE
ISSUER HAS FILED WITH THE SEC FOR MORE COMPLETE INFORMATION ABOUT THE ISSUER AND THIS OFFERING.
YOU MAY OBTAIN THESE DOCUMENTS FOR FREE BY VISITING EDGAR ON THE SEC
WEB SITE AT WWW.SEC.GOV OR BY
CLICKING ON THE LINK ABOVE. ALTERNATIVELY, THE ISSUER, ANY UNDERWRITER OR ANY DEALER
PARTICIPATING IN THE OFFERING WILL ARRANGE TO SEND TO YOU THE PROSPECTUS IF YOU REQUEST IT BY
CALLING (212) 667-7800.
ANY DISCLAIMERS OR OTHER NOTICES THAT MAY APPEAR BELOW OR ELSEWHERE WITHIN THE EMAIL ARE NOT
APPLICABLE TO THIS COMMUNICATION AND SHOULD BE DISREGARDED. SUCH DISCLAIMERS OR OTHER NOTICES WERE
AUTOMATICALLY GENERATED AS A RESULT OF THIS COMMUNICATION BEING SENT VIA AN ELECTRONIC MAIL SYSTEM.